Shao Yu-Yun, Lin Chia-Chi, Yang Chih-Hsin
Department of Oncology, National Taiwan University Hospital-Yunlin Branch, 360 Xingzhong, Yunlin, Taipei, Taiwan.
Discov Med. 2010 Jun;9(49):538-45.
Tyrosine kinase inhibitors of the epidermal growth factor receptor, gefitinib and erlotinib, have changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC). Many phase II or III studies have proven the efficacy of gefitinib or erlotinib as the first-line, second-line, or third-line treatment. However, it is not clear whether gefitinib or erlotinib has different activities in advanced NSCLC patients with different clinicopathological features or at different stages. We review the published clinical trials that used gefitinib or erlotinib in NSCLC and compare their efficacy. The selection criteria and efficacy measurement in these trials that might affect the final results of the studies are listed and discussed. The adequate-powered, direct comparisons of gefitinib against erlotinib under the same clinical scenarios are lacking. There is no evidence at present that the efficacy of these two agents in NSCLC is different.
表皮生长因子受体酪氨酸激酶抑制剂吉非替尼和厄洛替尼改变了晚期非小细胞肺癌（NSCLC）的治疗模式。许多II期或III期研究已证实吉非替尼或厄洛替尼作为一线、二线或三线治疗的疗效。然而，尚不清楚吉非替尼或厄洛替尼在具有不同临床病理特征或处于不同阶段的晚期NSCLC患者中是否具有不同活性。我们回顾了已发表的在NSCLC中使用吉非替尼或厄洛替尼的临床试验，并比较了它们的疗效。列出并讨论了这些试验中可能影响研究最终结果的选择标准和疗效测量方法。目前缺乏在相同临床情况下对吉非替尼与厄洛替尼进行充分有力的直接比较。目前没有证据表明这两种药物在NSCLC中的疗效存在差异。
